SCHEMBL23850795

SCHEMBL23850795

N#Cc1ccc(N2CCCC(O)C2)c([N+](=O)[O-])c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.65
MAPT P10636 7/20 0.54
MAPK1 P28482 4/20 0.54
TDP1 Q9NUW8 1/20 0.54
ALDH1A1 P00352 8/20 0.49
GAA P10253 5/20 0.49
ABCB1 P08183 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
VCAM1 P19320 1/20 0.44
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A3 P47895 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23850794 1.00 LMNA (0.65) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL23850888 1.00 LMNA (0.65) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL23850885 0.86 MAPT (0.54) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL23850889 0.86 MAPT (0.54) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL20524573 0.85 MAPT (0.62) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL31587859 0.82 ALDH1A1 (0.65) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL23850391 0.82 ALDH1A1 (0.65) LMNAMAPTMAPK1TDP1ALDH1A1
SCHEMBL23043575 0.81 LMNA (0.69) LMNAMAPTMAPK1ALDH1A1GAA
SCHEMBL23851235 0.79 SMARCA2 (0.46) LMNAMAPTALDH1A1GAAKMT2A
SCHEMBL23851510 0.79 MAPT (0.59) LMNAMAPTMAPK1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed
CN-113056305-A Compound (I) 格雷沃尔夫治疗有限公司 2021-06-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 LMNA 2596/4885MAPT 4705/4885MAPK1 4309/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR LMNA 2582/4885MAPT 302/4885MAPK1 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.